Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
OPHLY | OTC Markets | USD | Delayed | |
4528 | Tokyo | JPY | Delayed |
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer’s disease; Ongentys tablets for Parkinson’s disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.
Name | Age | Since | Title |
---|---|---|---|
Gyo Sagara | - | 2008 | CEO, President & Representative Director |
Yasuo Hishiyama | 50 | 2016 | Outside Audit & Supervisory Board Member |
Akiko Tanabe | 53 | 2020 | Outside Audit & Supervisory Board Member |
Hironobu Tanisaka | 62 | 2021 | Outside Audit Supervisory Board Member |
Toshihiro Tsujinaka | 59 | 2016 | Sr. EO, Executive Director of Sustainability Promotion Corporate Strategy & Planning and Director |
Katsuyoshi Nishimura | 69 | 2011 | Chairman of Audit & Supervisory Board |
Shusaku Nagae | 73 | 2021 | Independent Outside Director |
Toichi Takino | 55 | 2020 | Senior Managing Executive Officer, Head of Research Division & Director |
Kiyoaki Idemitsu | 59 | 2021 | Managing Executive Officer, GM of Development Division & Director |
Masao Nomura | 74 | 2018 | Independent Outside Director |
Akiko Okuno | 53 | 2020 | Independent Outside Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review